United States Health

Mesoblast (NASDAQ:MESO) reported FY2026 total revenue of $120.3 million, up from $17.2 million a year earlier, as the company recorded its first full U.S. commercial year of Ryoncil sales.

AbbVie (NYSE:ABBV) submitted a regulatory application to the European Medicines Agency for subcutaneous SKYRIZI (risankizumab) induction treatment in adults with moderately to severely active Crohn’s disease.

Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) reported positive Phase 3 results from the CROSSING trial of TEZSPIRE (tezepelumab-ekko), with the study meeting both primary endpoints in 368 patients with symptomatic eosinophilic esophagitis.

Daiichi Sankyo and AstraZeneca (NYSE:AZN) dosed the first patient in the phase 3 TROPION-Urothelial04 trial evaluating Datroway plus rilvegostomig or Datroway monotherapy in patients with high-risk muscle invasive urothelial cancer.

Biohaven (NYSE:BHVN) signed an exclusive global licensing agreement with SK Biopharmaceuticals for its Kv7 platform valued up to $795 million.

BeOne Medicines (NASDAQ:ONC) received U.S. FDA approval for TEVIMBRA (tislelizumab) combined with ZIIHERA (zanidatamab) and chemotherapy as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals (NASDAQ:JAZZ) received U.S. Food and Drug Administration approval for two Ziihera (zanidatamab-hrii) treatment regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

Anavex Life Sciences (NASDAQ:AVXL) reported third fiscal quarter 2026 results and provided updates on blarcamesine development programs targeting Alzheimer’s disease, Rett syndrome, and Fragile X syndrome.

Vyome Holdings (NASDAQ:HIND) reported second-quarter 2026 results and provided a corporate update, highlighting progress on VT-1953, its lead program for symptoms associated with malignant fungating wounds.

OrthoPediatrics (NASDAQ:KIDS) announced the full commercial launch of its 3P Pediatric Plating Platform Hip System in the United States after a limited launch phase that included more than 350 surgical implantations.

BioCryst (NASDAQ:BCRX) announced that Japan’s Ministry of Health, Labor and Welfare approved once-daily ORLADEYO (berotralstat) as a preventive treatment for pediatric hereditary angioedema (HAE) patients aged 2 to under 12 years.

Sagimet Biosciences (NASDAQ:SGMT) reported progress on its AURORA U.S. Phase 3 clinical trial evaluating denifanstat, a FASN inhibitor being developed for moderate to severe acne.